Outcome in patients with diabetes mellitus undergoing isolated surgical aortic valve replacement

Alina Cristina Iliescu, Mariana Floria, Mihaela Grecu, Ionuț Achiței, Cristina Luca, Grigore Tinică


Background: The risk scoring systems used in cardiac surgery (including EuroSCORE II) include only insulin-dependent diabetes. Diabetes mellitus (DM) is a marker of poor prognosis after surgical myocardial revascularization, but its impact in patients with isolated surgical aortic valve replacement (SAVR) has not been well established. Aim: We aimed to analyze differences in outcomes and surgical risk in patients with and without type 2 DM (T2DM), which underwent SAVR. Material and methods: We included retrospectively the patients hospitalized for SAVR between January 2000 and June 2014 in Cardiovascular Surgery Unit of Cardiovascular Diseases Institute. Preoperative parameters and early postoperative outcome in patients with and without T2DM were compared. Results: A number of 1191 patients were included (65.4±13 years; 67.8% men); 144 (12.07%) out of those were with T2DM. Biological prostheses were performed in 22% of patients. Mean age was higher in T2DM group (p=0.005). The mean EuroSCORE II risk score was 5.49±0.63 in T2DM and 4.89±0.17 in non-T2DM patients (p=0.579). In these 2 groups, preoperative left ventricular systolic function was comparable. Mean values of cardiopulmonary bypass time were 137.88±5.71 minutes in T2DM, 149.48±4.8 minutes in non-T2DM patients (p=0.714). The need of inotropic therapy was an important predictor for postoperative evolution (6±2 days in non-T2DM and 15±4 days in T2DM; p=0.008). Conclusions: Patients with T2DM undergoing SAVR have a non-significantly higher operative risk score comparing with non-T2DM patients. In spite of this, T2DM seems to be a risk factor that could worsen the postoperative outcome, by requiring prolonged inotropic treatment.


diabetes; aortic stenosis; aortic surgery; surgical risk

Full Text:



Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract 2017; 132:169-170.

Katz R, Wong ND, Kronmal R, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Circulation 2006; 113(17):2113–2119.

Otto CM, Bonow RO. Valvular Heart Disease. In Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E (eds) Braunwald’s Heart Disease. 9th edition. Philadelphia: Elsevier, 2012; 1468-1539.

Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33(19):2451-2496.

Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56(1):56-64.

Tadic M, Ilic S, Cuspidi C, et al. Left ventricular mechanics in untreated normotensive patients with type 2 diabetes mellitus: a two- and three-dimensional speckle tracking study. Echocardiography 2015; 32(6):947-955.

Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17):2735-2752.

Mathieu P, Després JP, Pibarot P. The valvulo-metabolic risk in calcific aortic valve disease. Can J Cardiol 2007; 23(Suppl B):32B-39B.

Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012; 41(4):734-744.

Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2002; 101(6):671-679.

Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368(9529):29-36.

Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 2015; 239(2):483-495.

Chaker Z, Badhwar V, Alqahtani F, et al. Sex differences in the utilization and outcomes of surgical aortic valve replacement for severe aortic stenosis. J Am Heart Assoc 2017; 6(9), pii:e006370. doi: 10.1161/JAHA.117.006370.

Lehmann S, Meyer A, Schroeter T, et al. Midterm durability and hemodynamic performance of a third-generation bovine pericardial prosthetic aortic valve: the Leipzig experience. Ann Thorac Surg 2017; 103(6):1933-1939.

St André AC, DelRossi A. Hemodynamic management of patients in the first 24 hours after cardiac surgery. Crit Care Med 2005; 33(9):2082-2093.

Pan W, Hindler K, Lee VV, Vaughn WK, Collard CD. Obesity in diabetic patients undergoing coronary artery bypass graft surgery is associated with increased postoperative morbidity. Anesthesiology 2006; 104(3):441-447.

Butterworth JF 4th, Legault C, Royster RL, Hammon JW Jr. Factors that predict the use of positive inotropic drug support after cardiac valve surgery. Anesth Analg 1998; 86(3):461-467.

Bergmark BA, Scirica BM, Steg PG, et al; SAVOR-TIMI 53 Investigators. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. Eur Heart J 2018; doi: 10.1093/eurheartj/ehx809.

DOI: http://dx.doi.org/10.22551/2018.18.0501.10118

Copyright (c) 2018 Alina Cristina Iliescu, Mariana Floria, Mihaela Grecu, Ionuț Achiței, Cristina Luca, Grigore Tinică

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975